2026-04-17T01:59:40Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/108982025-10-24T10:35:47Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Fung, Scott author Pan, Calvin Q. author Wong, Grace Lai-Hung author Seto, Wai-Kay author Ahn, Sang-Hoon author Chen, Chi-Yi author Buti Ferret, Maria author 2024-01-25T08:38:59Z 2024-01-25T08:38:59Z 2024-01 Atherosclerosis; Cardiovascular disease; Chronic hepatitis B Aterosclerosi; Malaltia cardiovascular; Hepatitis B crònica Aterosclerosis; Enfermedad cardiovascular; Hepatitis B crónica Background Patients with chronic hepatitis B (CHB) who switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) show changes in lipid profiles. Aim To evaluate how these changes affect cardiovascular risk. Methods This pooled analysis, based on two large prospective studies, evaluated fasting lipid profiles of patients with CHB who were treated with TAF 25 mg/day or TDF 300 mg/day for 96 weeks. Patients who fulfilled the American College of Cardiology criteria (age 40–79 years, high-density lipoprotein [HDL] 20–100 mg/dL, total cholesterol [TC] 130–320 mg/dL and systolic blood pressure 90–200 mmHg) required to assess 10-year atherosclerotic cardiovascular disease (ASCVD) risk with baseline lipid data and at least one post-baseline measurement were included in the ASCVD-risk population. The 10-year ASCVD risk was calculated for patients in this population, and changes from baseline to Week 96 were assessed using intermediate- (≥7.5%) and high-risk (≥20%) cut-offs. Results Among 1632 patients, 620 (38%) met the criteria for the ASCVD-risk population. At Week 96, fasting levels of all lipids, except TC:HDL ratio, were lower with TDF than TAF. No significant increase was observed in overall ASCVD risk or in any ASCVD-risk categories during the 96-week treatment period compared with baseline. A similar proportion of patients in the TAF and TDF treatment groups (1.3% and 2.3%, respectively; p = 0.34) reported cardiovascular events. Conclusion Despite on-treatment differences in lipid profiles with TAF and TDF, predicted cardiovascular risk and clinical events were similar for both groups after 96 weeks. http://hdl.handle.net/11351/10898 Hepatitis B - Tractament Medicaments antivírics Sistema cardiovascular - Malalties DISEASES::Virus Diseases::Virus Diseases::Hepatitis, Viral, Human::Hepatitis B::Hepatitis B, Chronic Other subheadings::Other subheadings::Other subheadings::/drug therapy DISEASES::Cardiovascular Diseases CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents ENFERMEDADES::virosis::virosis::hepatitis viral humana::hepatitis B::hepatitis B crónica Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia ENFERMEDADES::enfermedades cardiovasculares COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks